SOFIGATRAN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C24H44N4O4S
Molecular Weight	484.696
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCOC(=O)N[C@@H](C(=O)N1CCC[C@H]1C(=O)NC[C@H]2CC[C@H](N)CC2)C(C)(C)SC(C)C

InChI

InChIKey=MNMZVSQUWOILCZ-MUGJNUQGSA-N

InChI=1S/C24H44N4O4S/c1-6-14-32-23(31)27-20(24(4,5)33-16(2)3)22(30)28-13-7-8-19(28)21(29)26-15-17-9-11-18(25)12-10-17/h16-20H,6-15,25H2,1-5H3,(H,26,29)(H,27,31)/t17-,18-,19-,20-/m0/s1

HIDE SMILES / InChI

Description
Sources: https://adisinsight.springer.com/drugs/800015309 | https://www.ncbi.nlm.nih.gov/pubmed/20539909 | https://www.ncbi.nlm.nih.gov/pubmed/22742650

Mitsubishi Tanabe Pharma was developing Sofigatran, a thrombin inhibitor, for the treatment of deep vein thrombosis. Sofigatran, is a direct oral thrombin inhibitor with a competitive binding mechanism. It has been assessed in a phase II trial for the treatment of deep vein thrombosis The compound was in phase II clinical trial for the treatment of DVT. Results of this trial have not been published and the clinical development of sofigatran has been discontinued by Mitsubishi Tanabe Pharma in 2007.

Originator

Approval Year

PubMed

Title	Date	PubMed
New oral anticoagulant drugs in cardiovascular disease.	2010 Jul	20539909
Development and clinical applications of novel oral anticoagulants. Part II. Drugs under clinical investigation.	2012 Jun	22742650

Patents

Name

Type

Language

SOFIGATRAN

Official Name

English

MCC-977 BASE

Code

English

PROPYL ((1S)-1-((2S)-2-((TRANS-4-AMINOCYCLOHEXYLMETHYL)CARBAMOYL)PYRROLIDINE-1-CARBONYL)-2-METHYL-2-((PROPAN-2-YL)SULFANYL)PROPYL)CARBAMATE

Systematic Name

English

sofigatran [INN]

Common Name

English

Sofigatran [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C263